COMPOSITION :
Benoson® Tablet 0.5 mg, each tablet contains : Betamethasone 0.5 mg.
DESCRIPTIONS :
Benoson® with Betamethasone as active ingredient is available in tablet 0.5 mg.
INDICATIONS :
For diseases that require treatment with corticosteroids such as endocrine disorders, rheumatoid arthritis, collagen disease, dermatomyositis, allergic state, eye diseases, gastrointestinal disorders, hematologic disorders, neoplastic disease, edematous state, severe hypersensitivity reactions, systemic lupus erythematosus, anaphylaxis, mixed connective disease, polyarteritis nodosa, inflammatory skin disorders, minimal change nephrotic syndrome, acute interstitial nephritis, ulcerative colitis, Crohn’s disease, sarcoidosis, rheumatic carditis, hemolytic anemia (autoimmune), acute lymphocytic leukemia, malignant lymphoma, multiple myeloma, idiopathic thrombocytopenic purpura, immunosuppression in transplantation.
DOSAGE AND ADMINISTRATIONS :
- Adults : Dosage depends on disease state and clinical response.
- Short-term : 2 – 3 mg daily for the first few days, followed by a dose reduction from 0.25 – 0.5 mg every 2 – 5 days depending on clinical response.
- Rheumatoid arthritis : 0.5 – 2 mg daily. For maintenance therapy using minimum effective dose.
- Other conditions : 1.5 – 5 mg daily for 1 – 3 weeks until reach minimum effective dose. Large doses is required for diseases associated with tissue and ulcerative colitis.
CONTRAINDICATIONS :
- Systemic fungal infections.
- Hypersensitivity to drug.
- Peptic ulcer.
- Vaccination
- Rosacea, acne vulgaris, perioral dermatitis. Primary viral skin infections (such as herpes simplex, chicken pox).
- Bacterial infections, fungal, tuberculosis or purulent state of the eye.
- Glaucoma, herpes simplex keratitis (e.g. dendritic ulcers).
WARNINGS AND PRECAUTIONS :
- The use of these drugs can reduce the clinical symptoms of an infectious disease.
- Long-term use can reduce the body’s resistance against infectious diseases.
- Corticosteroids may activate latent amebiasis, therefore, before starting treatment, avoid the possibility of latent or active amebiasis in patients with diarrhea of unknown cause, or in those who return to tropic area.
- Careful use in patients with a history of peptic ulceration, history of mental disorders, renal impairment, hypertension, osteoporosis, myasthenia gravis, active tuberculosis, diabetes mellitus, glaucoma (or family history of glaucoma), thromboembolic tendencies, epilepsy, renal insufficiency, myopati due to corticosteroids, liver failure, herpes simplex keratitis, diverticulitis.
- The use of corticosteroids in patients with hypothyroidism and cytosis can increase the effects of corticosteroids.
- Steroids can increase or decrease the mobility and sperm count.
- Safety data of usage in pregnant women has not been sufficient. For those are born to mothers who received corticosteroids during pregnancy should be carefully monitored for signs of hypoadrenalism. Corticosteroid found in breast milk and may inhibit the growth, affect the production of endogenous corticosteroids or cause other undesirable effects. Patients should discontinue breast-feeding while taking this drug.
- Long-term use of corticosteroids in infants and children should be monitored because it can inhibit the development and growth.
- Long-term use in children can cause adrenal suppression.
PRESENTATION :
Benoson® Tablet 0.5 mg Box, 10 strips @ 10 tablets Reg. No. DKL7202313010A1
STORAGE :
STORE BELOW 30OC, PROTECT FROM LIGHT
ON MEDICAL PRESCRIPTION ONLY
Manufactured by :
PT. BERNOFARM
Sidoarjo – Indonesia
